43 results about "High affinity antibody" patented technology

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

The present application provides an anti-TIGIT antibody or antigen-binding fragment thereof and applications thereof, which comprises heavy chain variable region CDR1, CDR2, and CDR3 sequences shown in SEQ ID NOs: 1, 2, and 3, and light chain variable region CDR1, CDR2, and CDR3 sequences shown in SEQ ID NOs: 4, 5, and 6.

The invention discloses a halogen modified hapten for enhancing antibody titer and affinity as well as a preparation method and application of the halogen modified hapten, and belongs to the technical field of biochemical engineering. According to the method, an amantadine structure is innovatively and chemically modified, various halogens such as fluorine, chlorine and bromine are introduced, the AMA halogen modified hapten shown in the formula (I) is formed, and the traditional'most similar 'design principle is broken through. Compared with an unmodified hapten, the hapten modified by halogen in the invention has the advantages that the titer of the polyclonal antibody on amantadine can be obviously improved by 3.4-14 times; wherein the haptens A5 and A6 can obviously improve the titer of the monoclonal antibody to amantadine by 3-18 times, and the affinity is improved by 10.8-16.1 times. The invention provides a new thought and a new method for the rational design of the hapten of the small molecule compound and the preparation of the high-affinity antibody, and the related halogen modification type and quantity strategy can also provide valuable reference for the design of the hapten of other small molecule compounds.

The present invention provides antibodies that specifically bind to pepsinogen C and compositions and kits comprising such antibodies. Furthermore, polynucleotides encoding such antibodies, host cells expressing the antibodies, methods of producing such antibodies and diagnostic methods using such antibodies are provided.

The invention provides a Pirin-targeted nano antibody and application thereof. The nano antibody comprises a complementary determining region CDR which is a CDR1 shown in SEQ ID NO: 1 and a CDR3 shown in SEQ ID NO: 2, or a CDR1 shown in SEQ ID NO: 10 and a CDR3 shown in SEQ ID NO: 11, and an HV2 shown in an amino acid sequence of SEQ ID NO: 3 and an HV4 shown in an amino acid sequence of SEQ ID NO: 4, or an HV2 shown in SEQ ID NO: 12 and an HV4 shown in SEQ ID NO: 13. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force, the affinity is close to a nanomole level, and the nano antibody can be regarded as a high-affinity antibody; the compound can be developed into a high-specificity diagnostic reagent, and can be used as a therapeutic drug or an immune sensitizer.

The invention discloses a method for obtaining a single B cell and screening an antibody, and relates to the technical field of monoclonal antibody development. According to the invention, B cells are enriched through a magnetic bead anion selection method, and target B cells are screened by identifying a specific fluorescence signal mode. The method provided by the invention is helpful for improving the enrichment efficiency of the target B cells, reducing the enrichment cost, increasing the proportion of the positive cells after enrichment, also helpful for screening high-affinity antibodies, and improving the efficiency of antibody discovery.

The present application relates to the field of antibodies, and in particular, the present application provides a high affinity PADI2 antibody and a preparation method thereof. Through antibody screening experiments, eight high affinity PADI2 antibodies are screened, the antibodies can specifically bind to PADI2 protein, and have high affinity. Experimental results show that the antibodies of the present application exhibit excellent binding capacity in ELISA, Western blot and cell experiments, and can be used for detection, diagnosis and treatment of PADI2 related diseases.

The invention relates to the technical field of biological medicines, and particularly discloses an anti-PRRX2 monoclonal antibody and application thereof in detection of gemcitabine drug resistance of adenocarcinoma. The antibody is prepared through a hybridoma technology, a BALB / c mouse is immunized with a recombinant human PRRX2 protein, and a high-affinity antibody strain is obtained through cell fusion, screening and monocloning. Sequences of light and heavy chain variable regions of the antibody are shown as SEQ ID No: 7 and SEQ ID No: 8, and sequences of a CDR region are shown as SEQ ID No: 1-6. After the antibody is coupled with HRP, the antibody is used for Western Blot to detect PRRX2 expression in a pancreatic ductal adenocarcinoma (PDAC) patient sample, and the result shows that the detection sensitivity to a gemcitabine drug-resistant sample reaches 96.6%, and the specificity is 100%. The antibody disclosed by the invention has high specificity and stability, provides a reliable tool for clinical drug resistance detection, and is beneficial to formulating an individualized treatment strategy.

The invention relates to the field of antibodies, in particular to a high-affinity antibody pair for detecting PADI2 and application of the high-affinity antibody pair. The antibody pair consists of a first antibody and a second antibody. The antibody pair has good specificity and high affinity to human PADI2, can effectively detect trace PADI2 protein in human serum, improves the accuracy, reliability and sensitivity of an immunodetection result, and provides a more accurate and reliable antibody tool for detecting the PADI2 protein level.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

Disclosed herein is a method for obtaining antibody-producing cells that express antibody molecules exhibiting high binding affinity to an antigen, comprising: contacting a population of antibody-producing cells, including cells expressing antibody molecules against an antigen on their cell surface, with a first labeled form of the antigen to enable the antigen to bind to antibody molecules on the cell surface; subsequently contacting the cells with (i) an unlabeled form of the antigen, (ii) a second labeled form of the antigen, or (iii) both the unlabeled and second labeled forms of the antigen; and collecting cells that remain bound to the first labeled form of the antigen, thereby obtaining cells that express antibody molecules with high affinity to the antigen. This method makes it possible to obtain cells expressing high-affinity antibody molecules from a pool of antibody-producing cells expressing antibody molecules with different affinities.

The present application relates to the field of antibodies, and in particular, the present application provides a high affinity PADI2 antibody and a preparation method thereof. Through antibody screening experiments, eight high affinity PADI2 antibodies are screened, the antibodies can specifically bind to PADI2 protein, and have high affinity. Experimental results show that the antibodies of the present application exhibit excellent binding capacity in ELISA, Western blot and cell experiments, and can be used for detection, diagnosis and treatment of PADI2 related diseases.

The invention discloses a high-affinity nano antibody for resisting a nervous centralis specific protein S100beta or an antigen binding fragment of the high-affinity nano antibody and application of the high-affinity nano antibody, and belongs to the technical field of antibodies. The amino acid sequence of the nano antibody is as shown in SEQ ID NO: 2, and the nucleotide sequence of the nano antibody is as shown in SEQ ID NO: 1. The invention provides a high-affinity antibody with EC50 reaching 4.0 nM and a recombinant expression scheme capable of realizing large-scale production, and provides a high-affinity and low-cost S100beta nano antibody by reasonably designing a four-round screening strategy.

The present disclosure provides antibodies that specifically bind to pepsinogen A, as well as compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such antibodies, host cells expressing the antibodies, methods of producing such antibodies, and diagnostic methods using such antibodies.

Provided are an anti-FOLR1 antibody, and preparation therefor and the use thereof. The anti-FOLR1 antibody comprises a heavy chain variable region and a light chain variable region, or the anti-FOLR1 antibody comprises a heavy chain variable region; and both the heavy chain variable region and the light chain variable region comprise three complementarity determining regions. The provided anti-FOLR1 antibody is a high-affinity antibody capable of targeting FOLR1 on the surface of tumor cells, has binding affinity to FOLR1 on the surface of tumor cells similar as that of a control antibody, does not bind to other members of the FOLR family, and only specifically binds to FOLR1. Therefore, the anti-FOLR1 antibody can provide a new way for the development of products and technical means related to the prevention, treatment and detection of tumors such as ovarian cancer.

This invention provides an antibody combination for detecting interleukin-6 (IL-6), comprising a first antibody and / or a second antibody, each possessing a unique CDR fragment. Specific applications of this antibody combination are also provided. The advantages of this invention are that the antibody combination exhibits strong affinity for the IL-6 antigen, high detection sensitivity, ease of use, and rapid and stable detection. The concentration of IL-6 in normal human blood is approximately 4.2 pg / mL. Existing conventional low-affinity antibodies are insufficient for effective detection in this situation. However, the high-affinity antibody combination and the IL-6 quantitative detection kit containing this antibody combination using a double-antibody sandwich method provided by this invention can effectively achieve the quantitative detection of ultra-low concentrations of IL-6. Verification shows that the kit's sensitivity can reach 0.9 pg / mL.

The invention relates to the field of antibodies, in particular to a high-affinity antibody pair for detecting PADI2 and application of the high-affinity antibody pair. The antibody pair consists of a first antibody and a second antibody. The antibody pair has good specificity and high affinity to human PADI2, can effectively detect trace PADI2 protein in human serum, improves the accuracy, reliability and sensitivity of an immunodetection result, and provides a more accurate and reliable antibody tool for detecting the PADI2 protein level.

The present application relates to the technical field of biochemistry, and particularly relates to a kind of adamantylamine hydrophobic hapten and its synthesis method and application.The present application is based on adamantylamine target structure, introduces different hydrophobic spacer, improves the hydrophobicity of hapten.Then, hapten is coupled with carrier protein, and the immunogenicity of artificial antigen is evaluated.The present application explores the influence of the increase of hapten hydrophobicity on immunogenicity, which provides theoretical support for the rational design of hapten on one hand, and provides material basis for the preparation of high-affinity antibody of adamantylamine on the other hand.The present application provides a new idea for the rational design of small molecule compound hapten and the preparation of high-affinity antibody.

The present application relates to the field of antibodies, and in particular, the present application provides a high-affinity antibody pair for detecting PADI2 and application thereof. The antibody pair consists of a first antibody and a second antibody. The antibody pair has good specificity for human PADI2, high affinity, and can effectively detect trace amounts of PADI2 protein in human serum, thereby improving the accuracy, reliability and sensitivity of the immune detection result, and providing a more accurate and reliable antibody tool for detecting PADI2 protein level.

The application relates to the field of biological medicine, and particularly discloses a monoclonal antibody combined with human CD8 and a preparation method and application thereof. The antibody is obtained by combining single B cell sorting, gene cloning and mammalian cell expression technology after rabbit immunization of a CD8 polypeptide antigen, a New Zealand white rabbit is immunized by adopting a KLH coupled CD8 antigen polypeptide combined with a rapid immunoadjuvant, high-affinity antibody clones are obtained by single B cell sorting technology, and the antibody is prepared by recombination expression. The antibody is verified by ELISA and flow cytometry, has high titer and strong specificity, can effectively recognize human peripheral blood CD8+ T cells, and has a signal strength and a background signal-to-noise ratio which are significantly better than those of a traditional mouse-derived antibody. The application provides light and heavy chain variable region amino acid sequences of the antibody, realizes controllable preparation of the antibody and protection of intellectual property rights. The antibody can be widely applied to the fields of flow cytometry detection, immunohistochemistry, tumor immunotherapy monitoring and T cell function research, and has important scientific research and clinical application values.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

The invention provides a DeepVent-targeted nano antibody and application thereof. The nano antibody comprises a complementary determining region CDR (complementary determining region) which is CDR1 as shown in SEQ ID NO: 1, CDR3 as shown in SEQ ID NO: 2, HV2 as shown in an amino acid sequence as shown in SEQ ID NO: 3 and HV4 as shown in an amino acid sequence as shown in SEQ ID NO: 4. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force and affinity close to nanomole level, can be regarded as a high-affinity antibody, can be used for production and quality control, can be used for developing a next-generation'hot start 'PCR (polymerase chain reaction) reagent, and can be developed into a reversible and temperature-sensitive inhibitor.

The invention provides a nano antibody targeting an RBD structural domain of novel coronavirus spike protein and application of the nano antibody. The nanometer antibody comprises a complementary determining region CDR which is a CDR1 shown in SEQ ID NO: 1 and a CDR3 shown in SEQ ID NO: 2, or a CDR1 shown in SEQ ID NO: 10 and a CDR3 shown in SEQ ID NO: 11, or a CDR1 shown in SEQ ID NO: 18 and a CDR3 shown in SEQ ID NO: 18 and a CDR3 shown in SEQ ID NO: 25, and an HV2 shown in an amino acid sequence of SEQ ID NO: 3 and an HV4 shown in an amino acid sequence of SEQ ID NO: 4, or an HV2 shown in SEQ ID NO: 12 and an HV4 shown in SEQ ID NO: 13, or an HV2 shown in SEQ ID NO: 20 and an HV4 shown in SEQ ID NO: 4. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force and affinity close to nanomole level, and the nano antibody can be regarded as a high-affinity antibody and is used for developing a neutralizing antibody therapeutic drug of a targeted virus invasion mechanism and constructing a high-specificity serological diagnostic reagent and a variant monitoring platform.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

This invention provides an antibody combination for detecting transforming growth factor-β1 (TGF-β1), comprising a first antibody and / or a second antibody, each possessing a unique CDR fragment. Specific applications of this antibody combination are also provided. The advantages of this invention are that the antibody combination exhibits strong affinity for TGF-β1 antigen, high detection sensitivity, ease of use, and rapid and stable detection. The concentration of TGF-β1 in normal human serum is 28.4 ± 9.3 pg / ml. Existing conventional low-affinity antibodies are insufficient for effective detection in this situation. However, the high-affinity antibody combination and the TGF-β1 quantitative detection kit containing this antibody combination using a double-antibody sandwich method provided by this invention can effectively achieve the quantitative detection of ultra-low concentrations of TGF-β1. Verification shows that the kit's sensitivity can reach 4.9 pg / mL.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

This invention relates to the field of antibodies, specifically, it provides a high-affinity PADI2 antibody and its preparation method. Through antibody screening experiments, this invention obtained eight high-affinity PADI2 antibodies, which specifically bind to the PADI2 protein and exhibit high affinity. Experimental results show that the antibodies of this invention demonstrate excellent binding ability in ELISA, Western blot, and cell experiments, and can be used for the detection, diagnosis, and treatment of PADI2-related diseases.

The invention discloses a levofloxacin hapten, antigen and antibody as well as a preparation method and application thereof, and belongs to the technical field of small molecule immunodetection.A flexible spacer-(CH2) n-NH2 containing a terminal amino group is introduced to a nitrogen atom (namely a methyl connection site of methyl piperazine) at the tail end of a piperazine ring of a levofloxacin molecule, n is an integer of 2-8, and the flexible spacer-(CH2) n-NH2 is introduced into the nitrogen atom at the tail end of the piperazine ring of the levofloxacin molecule; therefore, a complete antigen with high immunogenicity and high specificity is constructed on the premise that a complete pharmacological structure of a quinolone mother nucleus is reserved, and a high-affinity antibody aiming at levofloxacin is obtained through induction.